Ranbaxy to Manufacture Pediatric ARV Combination

Ranbaxy Laboratories has received approval to manufacture and market antiretrovirals (ARVs) Coviro-LS kid and Coviro-LS kid DS for HIV-infected children in India.

Ranbaxy, which has 15 ARVs on the World Health Organization prequalification list, has filed these products with the organization for prequalification.

Coviro-LS kid contains lamivudine 20 mg and stavudine 5 mg, and Coviro-LS kid DS contains the drugs in 40-mg and 10-mg strengths, respectively, according to Ranbaxy.